Hydroxyurea treatment for chronic myeloid leukemia during pregnancy

Celıloğlu, Murat; Altunyurt, Sabahattin; Ündar, Bülent

doi:10.3109/00016340009169201

Cited by 15 publications

(14 citation statements)

References 6 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…66 For those who need intervention because of a very high WBC or evidence of progression, we prefer to use leukapheresis. Use of hydroxyurea [67][68][69] and IFN [69][70][71] have been reported in pregnancy with no complications, but the experience is limited. We prefer to use short pulses of hydroxyurea to control excessive rises in WBC; IFN can be used, but it may take longer time to obtain a hematologic response and is also associated with more adverse events.…”

Section: Pregnancymentioning

confidence: 99%

How I treat newly diagnosed chronic phase CML

Cortes

Kantarjian

2012

Blood

103

View full text Add to dashboard Cite

The progress made in the understanding of chronic myeloid leukemia (CML) since the recognition of a common chromosomal abnormality to the introduction of ever more effective tyrosine kinase inhibitors is unprecedented in cancer. The expected survival for patients diagnosed with CML today, if properly managed, is probably similar to that of the general population. When managing patients with CML the goal is to achieve the best longterm outcome and we should base the treatment decisions on the data available. The results from cytogenetic and molecular analyses have to be interpreted judiciously and all available treatment options integrated into the treatment plan properly. The availability of several treatment options in CML is an asset, but the temptation of rapid succession of treatment changes because of perceived suboptimal response or for adverse events that could be managed needs to be avoided. Any decision to change therapy needs to weigh the expected long-term outcome with the current option versus the true expectations with any new option, particularly as it relates to irreversible outcomes, such as transformation to blast phase and death. In this manuscript, we discuss the treatment approach that has helped us manage successfully a large CML population. (Blood. 2012;120(7):1390-1397)

show abstract

Section: Pregnancymentioning

confidence: 99%

How I treat newly diagnosed chronic phase CML

Cortes

Kantarjian

2012

Blood

103

View full text Add to dashboard Cite

show abstract

“…The incidence of CML associated with pregnancy is estimated to be 1/75000 pregnancies (Celiloglu et al, 2000). The diagnostic approach is identical as in non-pregnant patients.…”

Section: Chronic Leukemia In Pregnancy 521 Chronic Myelogenous Leukmentioning

confidence: 87%

Hematologic Malignancies in Pregnancy

Vandenbriele¹,

Vassou²,

Pentheroudakis³

et al. 2011

Acute Leukemia - The Scientist's Perspective and Challenge

View full text Add to dashboard Cite

“…[1] Diagnosis during pregnancy is mostly made in the second or third trimesters because the early symptoms are non-specific. Because of its chronic course, it is usually managed conservatively during pregnancy by leukapheresis, [2] hydroxyurea, [3] interferon, [4] and imatinib. [5] Pregnancy per se does not affect CML, but there are the risks of leukostasis and placental insuffiency with consequent low birth weight, premature delivery and increased mortality.…”

Section: Discussionmentioning

confidence: 99%

Chronic myeloid leukemia with pregnancy: Successful management of pregnancy and delivery with hydroxyurea and imatinib continued till delivery

2013

View full text Add to dashboard Cite

Chronic myeloid leukemia (CML) is a rare disease in pregnancy. Our aim is to present a 37 weeks of pregnant woman with chronic myelogenous leukemia. A 27 Years in multigravi (gravida 5, parity: 4), at 37 weeks gestation was admitted with the diagnosis of painful pregnancy and CML. Physical examination findings were normal, complete blood count and peripheral blood smear results were consistent with CML. The patient was diagnosed CML in the 30th week of pregnancy and were treated with hydroxyurea and interferon. Treatment depends on the mother and the fetus did not develop any side effects. Our patient with CML is interesting due to lack of perinatal effects and take the diagnosis at an early age. CML diagnosed during pregnancy requires a multidisciplinary approach and hydroxyurea and interferon treatment on the mother and fetus are at low risk of inducing adverse effects.

show abstract

Hydroxyurea treatment for chronic myeloid leukemia during pregnancy

Cited by 15 publications

References 6 publications

How I treat newly diagnosed chronic phase CML

How I treat newly diagnosed chronic phase CML

Hematologic Malignancies in Pregnancy

Chronic myeloid leukemia with pregnancy: Successful management of pregnancy and delivery with hydroxyurea and imatinib continued till delivery

Contact Info

Product

Resources

About